- Not Fee assured
- Verified this account
I am a Medical Oncologist with 17 years experience at Consultant level and specialise in the medical treatment or a range of cancers. I trained in several London teaching Hospitals including the Royal Marsden and also undertook as research degree ai the Institute of Cancer research London. Research continues to be an integral part of my practice in order to drive new developments in care fore my patients as well as providing them with the latest and most cutting-edge treatments.
Areas of interest
Neuroendocrine tumours; Lung cancer; Malignant Mesothelioma; Malignant melanoma; Colorectal (bowel) cancer; Kidney (renal) cancer; Cancer of Unknown Primary; Testicular cancer;
Current NHS consultant posts held
Consultant Medical Oncologist
Gloucestershire Oncology Centre
Cheltenham General Hospital
Predictors of response to treatment.
Supportive care of patients undergoing anti-cancer therapy.
Patient decision aids in Cancer of Unknown Primary
3. ASCO Merit Award at the May 1999 Annual meeting in Atlanta, Georgia, for a poster discussion presentation entitled “Genomic Study Of Patients With Advanced Colorectal Cancer Treated With Raltitrexed (‘Tomudex’)”.
Chief Medical Officer’s Award for services to Commercial Research 2015.
Abbvie Pharmaceuticals Gold Star Award for recruitment into Lung Cancer Studies 2015.
English, Italian and Maltese.
FARRUGIA DC, NORMAN AR, et al. Unknown Primary Carcinoma: Randomised Studies are needed to identify optimal Treatments and their Benefits. Eur J of Cancer. 1996; 32A: 2256-2261.
D C FARRUGIA, A R NORMAN AND D CUNNINGHAM. Single Agent Infusional 5-FU is not Effective Second Line Therapy after Tomudex in Advanced Colorectal Cancer. Eur J of Cancer. 1998; 34(7): 987-991.
D FARRUGIA, W ANSELL, et al. Stilboestrol Plus Adrenal Suppression as Salvage Treatment for Patients Failing Treatment with Luteinizing Hormone-Releasing hormone Analogues and Orchidectomy. Br J Urol. 2000; 85: 1-5.
OLIVER, RTD, FARRUGIA D, et al. Potential of Intermittent Hormone Therapy for M+ and M0 Prostate Cancer Patients. Prostate Cancer and Prostatic Diseases 2000; 3: 286-289.
FORD, H E, MITCHELL F, CUNNINGHAM D, FARRUGIA D C et al. "Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331." Clin Cancer Res 2002; 8(1): 103-9.
FARRUGIA D, FORD H, et al. Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed. Clin Cancer Res 2003; 9: 792-801.
GUGLANI S, FARRUGIA D, et al. Reversible Life-Threatening Encephalopathy In The Absence Of Hepatic Failure Following Conventional Doses Of Docetaxel. Clin Oncol (R Coll Radiol). 2003; 15(3): 160-1.
LANE, T M, ANSELL W, FARRUGIA D, et al. "Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression." Urol Int 2004; 73(2): 117-22.
SEYMOUR, M. T., TRIGONIS I, FINAN PJ, et al. (2007). "A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer." Eur J Surg Oncol 30: 30.
MEDLEY, L., A. N. MOREL, D FARRUGIA et al. (2011). "Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours." Br J Cancer 104(7): 1067-70.
PAYNE, M. J., K. ARGYROPOULOU, LORIGAN, P., MCALEER, J. J., FARRUGIA, D., et al. (2013). "Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence." J Clin Oncol. Dec 16.
DECATRIS, M. P., FARRUGIA, D. et al. (2016). "Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer." J Clin Oncol 34(8): 884-886.
Courses offered to GPs
Update lectures to GPs on Cancer of Unknown Primary, Skin cancer, Kidney cancer.
- MD University of Malta 1987
- PhD University of London 1998
- FRCP Royal College of Physicians, London 2004
- CCST Medical Oncology JCHMT, London 2000
Affiliations / memberships
1. American Association of Clinical Oncology (ASCO)
2. Association of Cancer Physicians (ACP), UK
3. European Society of Medical Oncology (ESMO)
4. British Thoracic Oncology Group (BTOG)
5. EORTC melanoma group
6. UK Melanoma FOCUS Group
7. UK Neuroendocrine Tumour Study Group (UKINETS)
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Oncology Helpline, Cheltenham General Hospital.